4502 — Takeda Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapNeutral

Annual income statement for Takeda Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	3,197,812	3,569,006	4,027,478	4,263,762	4,581,551
Cost of Revenue
Gross Profit	2,203,504	2,462,160	2,783,406	2,837,084	3,001,334
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	2,596,860	3,123,808	3,494,185	4,014,490	4,238,965
Operating Profit	600,952	445,198	533,293	249,272	342,586
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	366,235	302,571	375,090	52,791	175,084
Provision for Income Taxes
Net Income After Taxes	376,171	230,166	317,038	144,197	108,143
Minority Interest
Net Income Before Extraordinary Items
Net Income	376,005	230,059	317,017	144,067	107,928
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	376,005	230,059	317,017	144,067	106,148
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	129	194	211	168	67.2
Dividends per Share